The arterial input function is crucial in pharmacokinetic analysis of dynamic contrast-enhanced MRI data. Among other artifacts in arterial input function quantification, the blood inflow effect and nonideal radiofrequency spoiling can induce large measurement errors with subsequent reduction of accuracy in the pharmacokinetic parameters. These errors were investigated for a 3D spoiled gradient-echo sequence using a pulsatile flow phantom and a total of 144 typical imaging settings. In the presence of large inflow effects, results showed poor average accuracy and large spread between imaging settings, when the standard spoiled gradient-echo signal equation was used in the analysis. For example, one of the investigated inflow conditions resulted in a mean error of about 40% and a spread, given by the coefficient of variation, of 20% for K trans . Minimizing inflow effects by appropriate slice placement, combined with compensation for nonideal radiofrequency spoiling, significantly improved the results, but they remained poorer than without flow (e.g., 3-4 times larger coefficient of variation for K trans ). It was concluded that the 3D spoiled gradient-echo sequence is not optimal for accurate arterial input function quantification and that correction for nonideal radiofrequency spoiling in combination with inflow minimizing slice placement should be used to reduce the errors. Magn Reson Med 65:1670-1679, 2011. V C 2011 Wiley-Liss, Inc.Key words: dynamic contrast-enhanced MRI; arterial input function; blood flow effects; RF spoiling Dynamic contrast-enhanced MRI (DCE-MRI) is a technique based on the acquisition of a series of images before, during, and after intravenous administration of contrast agent (CA). CA concentration curves can be derived from the images, and tissue specific quantitative pharmacokinetic parameters can subsequently be obtained by appropriate modeling (1).This technique has many applications, for example, in clinical oncology. Biomarkers for drug efficacy and clinical outcome, derived from DCE-MRI, can potentially increase cost efficiency and thus facilitate early phase clinical trials of antiangiogenic and vascular disrupting agents. In the clinical setting, DCE-MRI can provide noninvasive tumor grading as well as predict treatment outcome (2,3).In general, the data acquisition of quantitative DCE-MRI consists of two steps. First, baseline T 1 is quantified, typically by using a gradient echo (GRE) variable flip angle (FA) method (4). After that, a dynamic scan is performed in which the first few images are acquired before the injection of CA (i.e., the baseline signal), and the remaining images are acquired during and up to several minutes after the injection. Then, the T 1 relaxation time is estimated from baseline and dynamic scan images. Under the assumption of the fast exchange limit (5), one can estimate the concentration of CA from a linear relationship between the concentration and the T 1 relaxation rate provided that the relaxivity of the CA is known. The relaxivity is typically ...